ZOVIRAX SUSPENSION 200 mg5 ml

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

ACYCLOVIR

Available from:

GLAXOSMITHKLINE PTE LTD

ATC code:

J05AB01

Dosage:

200 mg/5 ml

Pharmaceutical form:

SUSPENSION

Composition:

ACYCLOVIR 200 mg/5 ml

Administration route:

ORAL

Prescription type:

Prescription Only

Manufactured by:

ASPEN BAD OLDESLOE GMBH

Authorization status:

ACTIVE

Authorization date:

1988-05-14

Patient Information leaflet

1 

ZOVIRAX
TM 
Oral Formulations  
ACICLOVIR 

QUALITATIVE AND QUANTITATIVE COMPOSITION 
Tablets:  
Zovirax Tablets 200mg are white, round, biconvex tablets impressed
“GXCL3” on one side and 
plain on the other, each tablet containing 200mg aciclovir.  
Zovirax Tablets 400mg are pink, shield-shaped tablets
impressed ‘Zovirax 400’ on one face and 
a triangle on the reverse, each tablet containing 400mg aciclovir. 
Zovirax Dispersible Tablets 800mg are white, elongated-biconvex,
film-coated dispersible 
tablets impressed “Zovirax 800” on one face, with the other face
scored and contain 800mg 
aciclovir in each tablet.   
Oral Suspension: 
Zovirax Suspension 200mg/5ml is a white, banana-flavoured, oral
suspension containing 200mg 
acyclovir in each 5ml.  

PHARMACEUTICAL FORM 
Tablets. 
Dispersible tablets 
Oral suspension. 

CLINICAL PARTICULARS 
INDICATIONS 
Zovirax Oral Formulations are indicated for the treatment of Herpes
simplex virus infections of 
the skin and mucous membranes, including initial and recurrent
genital herpes.  
Zovirax Oral Formulations are indicated for the suppression
(prevention of recurrence) of 
recurrent Herpes simplex infections in immune-competent patients.  
Zovirax Oral Formulations are indicated for the prophylaxis of Herpes
simplex infections in 
immune-compromised patients.  
2 

Zovirax Oral Formulations are indicated for treatment of Varicella
(Chickenpox) and Herpes 
zoster (Shingles) infections. Studies have
shown that early treatment of shingles with Zovirax 
has a beneficial effect on pain and can reduce the incidence of
post-herpetic neuralgia (zoster-
associated pain).  
DOSAGE AND ADMINISTRATION 
_Dosage for treatment of Herpes simplex in adults _
For the treatment of Herpes simplex infections, 200mg Zovirax should
be taken five times daily 
at approximately four-hourly intervals omitting the night time dose.
Treatment should continue 
for five days but in severe initial infections m

Summary of Product characteristics

1
ZOVIRAX
Oral Formulations
ACICLOVIR
QUALITATIVE AND QUANTITATIVE COMPOSITION
Tablets:
Zovirax Tablets 200mg are white, round, biconvex tablets impressed
“GXCL3” on one side and
plain on the other, each tablet containing 200mg aciclovir.
Zovirax Dispersible Tablets 800mg are white, film-coated oval biconvex
tablets, branded
“GXCG1” on one face and plain on the other and contain 800mg
aciclovir in each tablet.
Oral Suspension:
Zovirax Suspension 200mg/5mL is a white, banana-flavoured, oral
suspension containing 200mg
aciclovir in each 5mL.
CLINICAL INFORMATION
INDICATIONS
Zovirax Oral Formulations are indicated for the treatment of Herpes
simplex virus infections of
the skin and mucous membranes, including initial and recurrent genital
herpes.
Zovirax Oral Formulations are indicated for the suppression
(prevention of recurrence) of
recurrent Herpes simplex infections in immune-competent patients.
Zovirax Oral Formulations are indicated for the prophylaxis of Herpes
simplex infections in
immune-compromised patients.
Zovirax Oral Formulations are indicated for treatment of Varicella
(Chickenpox) and Herpes
zoster (Shingles) infections. Studies have shown that early treatment
of shingles with Zovirax
2
has a beneficial effect on pain and can reduce the incidence of
post-herpetic neuralgia (zoster-
associated pain).
DOSAGE AND ADMINISTRATION
_Pharmaceutical Form: _
Tablets.
Dispersible tablets.
Oral suspension.
_Dosage for treatment of Herpes simplex in adults _
_ _
For the treatment of Herpes simplex infections, 200mg Zovirax should
be taken five times daily
at approximately four-hourly intervals omitting the night time dose.
Treatment should continue
for five days but in severe initial infections may have to be
extended.
In severely immune-compromised patients (e.g., after marrow
transplant) or in patients with
impaired absorption from the gut the dose can be doubled to 400mg or,
alternatively, intravenous
dosing could be considered.
Dosing should begin as early as possible after the start of an
infection;